Deletion Variants within the NF-kB Activation Domain of the LMP1 Oncogene in Acquired Immunodeficiency Syndrome-Related Large Cell Lymphomas, in Prelymphomas and Atypical Lymphoproliferations

Leukemia and Lymphoma

Volumn 26, Issue 42067, 1997, Pages 239-250

  Bercer, Christoph ^a   Brousset, Pierre ^b   Mcquain, Cathy ^a   Knecht, Hans ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

AIDS related large cell lymphoma; LMP1 oncogene; NF kB activation; prelymphoma

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MEMBRANE PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CARBOXY TERMINAL SEQUENCE; CELL TRANSFORMATION; CELLULAR IMMUNITY; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; GENE DELETION; HUMAN; HYPERPLASIA; IMMUNOGLOBULIN VARIABLE REGION; LARGE CELL LYMPHOMA; LYMPHOCYTE PROLIFERATION; ONCOGENE; PRECANCER; PRIORITY JOURNAL; PROLYMPHOCYTE; REVIEW;

AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; GENE DELETION; HUMANS; LYMPHOMA, AIDS-RELATED; LYMPHOMA, LARGE-CELL; LYMPHOPROLIFERATIVE DISORDERS; MOLECULAR SEQUENCE DATA; NF-KAPPA B; PRECANCEROUS CONDITIONS; PROTEIN STRUCTURE, TERTIARY; VIRAL MATRIX PROTEINS;

EID: 0030756723     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428199709051773     Document Type: Article

References (69)

1. Henle G., Henle W., Diehl V. Relation of Burkitt's tumor-associated herpes-type virus to infectious mononucleosis. Proc. Natl. Acad. Sci. USA 1968; 59: 94 – 101
2. Epstein M.A., Achong B.G., Barr Y.M. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1964; 702 – 703
3. Fahraeus R., Fu H.L., Ernberg I., Finke J., Rowe M., Klein G., Falk K., Nilsson E., Yaday M., Busson P., Tursz T., Kallin B. Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int. J. Cancer 1988; 42: 329 – 338
4. Brousset P., Butet V., Chittal S., Selves J., Delsol G. Comparison of in situ hybridization using different nonisotopic probes for detection of Epstein-Barr virus in nasopharyngeal carcinoma and immunohistochemical correlation with anti-latent membrane protein antibody. Lab. Invest. 1992; 67: 457 – 464
5. Crawford D.H., Thomas J.A., Janossy G., Sweny P., Fernando O.N., Moorhead J.F., Thompson J.H. Epstein-Barr virus nuclear antigen positive lymphoma after cyclosporin a treatment in patient with renal allograft. Lancet 1980; 1355 – 1356
6. Hamilton-Dutoit S.J., Rea D., Raphael M., Sandvej K., Delecluse H.J., Gisselbrecht G., Marelle L., van Krieken J. H. H. M., Pallesen G. Epstein-Barr virus-latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related Non-Hodgkin's lymphoma. Blood 1993; 82: 619 – 624
7. Weiss L.M., Movahed L.A., Warnke R.A., Sklar J. Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. N. Engl. J. Med. 1989; 320: 502 – 506
8. Knecht H., Sahli R., Shaw P., Meyer C., Bachmann E., Odermatt B.F. Detection of Epstein-Barr virus DNA by polymerase chain reaction in lymph node biopsies from patients with angioimmunoblastic lymphadenopathy. Br. J. Haematol. 1990; 75: 610 – 614
9. Bankier A.T., Deininger P.L., Satchwell S.C., Baer R., Farrell P.J., Barrell G.B. DNA sequence analysis of the EcoR1 Dhet fragment of B95–8 Epstein-Barr virus containing the terminal repeat sequences. Mol. Biol, Med. 1983; 1: 425 – 145
10. Fennewald S., van Santen V., Kieff E. Nucleotide sequence of a mRNA transcribed in latent growth-transforming virus infection indicates that it may encode a membrane protein. J. Virol 1984; 51: 411 – 419
11. Hennessy K., Fennewald S., Hummel M., Cole T., Kieff E. A membrane protein encoded by Epstein-Barr virus in latent growth-transforming infection. Proc. Natl. Acad. Sci. USA 1984; 81: 7207 – 7211
12. Deacon E.M., Pallesen G., Niedobitek G., Crocker J., Brooks L., Rickinson A.B., Young L.S. Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in malignant cells. J. Exp. Med. 1993; 177: 339 – 349
13. Chen F., Hu L.F., Ernberg I., Klein G., Winberg G. Coupled transcription of Epstein-Barr virus latent memhrane protein (LMP)-1 and LMP-2B genes in nasopharyngeal carcinomas. J. Gen. Virol. 1995; 76: 131 – 138
14. Tierney R.J., Steven N., Young L.S., Rickinson A.B. Epstein-Barr virus latency in blood mononuclear cells: Analysis of viral gene transcription during primary infection and in the carrier state. J. Virol. 1994; 68: 7374 – 7385
15. Thomas J.A., Hotchin N.A., Allday M.J., Amlot P., Rose M., Yacoub M., Crawford D.H. Immunohistology of Epstein-Baar virus-associated antigens in B cell disorders from immunocompromised individuals. Transplantation 1990; 49: 944 – 953
16. Wang D., Liebowitz D., Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms estahlished rodent cells. Cell 1988; 43: 831 – 840
17. Fuhraeus R., Rymo L., Rhim J.S., Klein G. Morphological transformation of human keratinocytes expressing the LMP gene of Epstein-Barr virus. Nature 1990; 345: 437 – 449
18. Dawson C.W., Rickinson A.B., Young L.S. Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation. Nature 1990; 344: 777 – 780
19. Peng M., Lundgren E. Transient expression of the Epstein-Barr virus LMP1 gene in human primary B cells induces cellulat- activation and DNA synthesis. Oncogene 1992; 7: 1775 – 1782
20. Henderson S., Rowe M., Gregory C., Croom-Carter D., Wang F., Lonpnecker R., Kieff E., Rickinson A. Induction or bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 1991; 65: 1107 – 1115
21. Mosialos G., Birkenbach M., Yalamanchili R., Van Arsdale T., Ware C., Kieff E. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 1995; 80: 380 – 399
22. Mitchell T., Sugden R. Stimulation of NF-kB-mediated transcription by mutant derivatives of the latent membrane protein of Epstein-Barr virus. J. Virol. 1995; 69: 2068 – 2976
23. Huen D.S., Henderson S.A., Croon-Carter D., Rowe M. The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kB and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Ontogene 1995; 10: 549 – 560
24. Herrero J.A., Mathew P., Paya C.V. LMP-1 activates NP-kB by targeting the inhibitory molecule IkBα. J. Virol. 1095; 69: 2168 – 2174
25. Baeuerle P.A., Henkel T. Function and activation of NF-kB in the immune system. Annu. Rev. Immunol. 1994; 12: 141 – 179
26. Hu L.F., Zabarovsky E.R., Chen F., Cao S.F., Ernberg I., Klein G., Winberg G. Isolation and sequencing of the Epstein-Barr virus BNLF-1 gene (LMP1) from a Chinese nasopharyngeal carcinoma. J. Gen. Virol. 1991; 72: 2399 – 2400
27. Chang Y.S., Su I.J., Chung P.J., Shu C.H., Ng C.K., Wu S.J., Liu S.T. Detection ot en Epstein-Barr-virus variant in T-cell-lymphoma tissues identical to the distinct strain observed in nasopharyngeal carcinoma in the Taiwanes population. Int. J. Cancer 1995; 62: 673 – 677
28. Knecht H., Bachmann E., Brousset P., Sandvej K., Nadal D., Bachmann F., Odermatt B.F., Delsol G., Pallesen G. Deletions within the LMP1 oncogene of Epstein-Barr virus are clustered in Hodgkin's disease and identical to those observed in nasopharyngeal carcinoma. Blood 1993; 82: 2937 – 2942
29. Knecht H., Bachmann E., Joske D. J. L., Sahli R., Emery-Goodman A., Casanova J.L., Zilic M., Bachmann F., Odermatt B.F. Molecular anaylsis of the LMP (latent membrane protein) oncogene in Hodgkin's disease. Leukemia 1993; 7: 580 – 585
30. Knecht H., Bachmann E., Brousset P., Rothenberger S., Einsele If., Lestou V.S., Delsol C., Bachmann F., Ambros P.F., Odermatt R.F. Mutational hot spots within the carboxy terminal region of the LMP1 oncogene of Epstein-Barr virus are frequent in lymphoproliferative disorders. Oncogene 1995; 10: 523 – 528
31. Santon A., Manzanal A.I., Campo E., Bellas C. Deletions in the Epstein-Barr virus latent membrane prtrtein- 1 oncogene in Hodgkin's disease. J. Clin. Pathol.: Mol. Pathol. 1995; 48: M184 – M187
32. Knecht H., Raphael M., McQuain C., Kothenberger S., Pihan G., Bachmann E., Ryan S., Kittler E. L. W., Quesenberry P.J., Schlaifer D., Woda B.A., Brousset P. Deletion variants within the NF-kB activation domain of the LMP1 oncogene prevail in AIDS-related large cell lymphomas and HIV-negative atypical lymphoproliferations. Blood 1996; 87: 876 – 881
33. Palefsky J.M., Berline J., Penarandu M.E., Lennette E.T., Greenspan D., Greenspan J.S. Sequence variation of latent membrane protein-1 of Epstein-Barr virus strains associated with hairy leukoplakia. J. Infect. Dis. 1996; 173: 710 – 714
34. Walling D.M., Clark N.M., Markovitz D.M., Frank T.S., Braun D.K., Eisenberg E., Krutchkoff D.J., Felix D.H., Raab-Traub N. Epstein-Barr cirus coinfection and recombination in non-human immunodeficiency virus association. ated oral hairy leukoplakia. J. Infect. Dis. 1995; 171: 1122 – 1130
35. Berger C., McQuain C., Sullivan J., Nadal D., Quesenberry P.J., Knecht H. The LMP1 30 base pair deletion variant with enhanced oncogenic activity prevails in acute infectious mononucleosis and EBV-associated tonsillar hyperplasia. Blood 1996, Abstr. (in press)
36. Knecht H., McQuain C., Martin J., Drexler H.G., Rothenberger S., Berger C., Bachmann E., Kittler E. L. W., Odermati B.F., Quesenberry P.J. Expression of the LMP1 oncoprotein in the EBV negative Hodgkin's disease cell line L-428 is associated with Reed-Sternberg cell morphology. Oncogene 1996; 13: 947 – 953
37. Li S.N., Chang Y.S., Liu S.T. Effect of a 10-amino acid deletion on the oncogenic activity of latent membrane protein 1 of Epstein-Barr virus. Oncogene 1996; 12: 2129 – 2135
38. Sandvej K., Peh S.C., Andresen B.S., Pallesen G. Identification of potential hot spots in the carboxy-termind part of the Epstein-Barr virus (EBV) BNLF-1 gene in both malignant and benign EBV-associated diseases: High frequency of a 30-bp deletion in Malaysian and Danish peripheral T-cell lymphomas. Blood 1994; 84: 4053 – 4060
39. Vasef M.A., Kamel O.W., Chen Y.Y., Medeiros J., Weiss L.M., Abbot S.D. Detection of Epstein-Barr virus in multiple sites involved by Hodgkin's disease. Am. J. Pathol. 1995; 147: 1408 – 1415
40. Kingma D.W., Weiss W.B., Jaffe E.S., Kumar S., Frekko K., Raffeld M. Epstein-Barr virus latent membrane protein-1 oncogene deletions: correlations with malignancy in Epstein-Barr virus-associated lymphoproliferative disorders and malignant lymphomas. Blood 1996; 88: 242 – 251
41. Chen W.C., Chen Y.Y., Bacchi M.M., Bacchi C.E., Alvarenga M. W. L. M. Genotyping of Epstein-Barr virus in Brazilian Burkitt's lymphoma and reactive lymphoid tissue. Am. J. Pathol. 1996; 148: 17 – 23
42. Brousset P., Schlaifer D., Meggetto F., Bachmann E., Rothenberger S., Delsol G., Knecht H. Persistance of the same viral strain in early and late relapses of Epstein-Barr virus associated Hodgkin's disease. Blood 1994; 84: 2441 – 2451
43. Knecht H., Martius F., Bachmann E., Hoffmann T., Zimmermann D.R., Rothenberger S., Sandvej K., Wegmann W., Hurwitz N., Odermatt B.F., Kummer H., Pallesen G. A deletion mutant of the LMP1 oncogene of Epstein-Barr virus is associated with transformation of angioimmunoblastic lymphadenopathy into B-immunoblastic lymphoma. Leukemia 1995; 9: 458 – 465
44. Kershaw G.R., McQuain C., Berger C., Pihan G., Odermatt B.F., Quesenberry P.J., Woda B.A., Knecht H. Selective outgrowth of a posttransplant B-immunoblastic lymphoma expressing a LMP1 deletion variant. 1996, (Submitted)
45. Klein C., Rothenberger S., Niemeyer C., Bachmann E., Odermatt B., Boehm N., Brandis M., Knecht H. EBV-associated lymphoproliferative syndrome with a distinct 69 hase-pair deletion in the LMP-1 oncogene. Br. J. Haematol. 1995; 91: 938 – 940
46. Larcher C., McQuain C., Berger C., Mitterer M., Huemer H.P., Quesenberry P.J., Knecht H. Epstein-Barr virus associated persistent polyclonal B-cell lymphocytosis with a distinct 69 base pair deletion in the LMP-1 oncogene. Ann. Haematol. 1996, (in press)
47. Grunewald V., Bonnet M., Martel Renoir D., Cochet C., Joab I. Heterogeneity within the Epstein-Barr virus transactivator, zebra, derived from nasopharyngeal carcinoma. Epstein-Barr Virus & Associated Diseases 1994; 208, (Abstract)
48. Chen M.L., Tsai C.N., Liang C.L., Shu C.H., Hang C.R., Sulitzeanu D., Liu S.T., Chang Y.S. Cloning and characterization of the latent membrane protein (LMP) of a specific Epstein-Barr virus variant derived from the nasopharyngeal carcinoma in the Taiwanese population. Oncogene 1992; 7: 2131 – 2140
49. Trivedi P., Hu L.F., Chen F., Christensson B., Masucci M.G., Klein G., Winberg G. Epstein-Barr virus (EBV)-encoded membrane protein LMP1 from a nasopharyngeal carcinoma is non-immunogenic in a murine model system, in contract to a B cell-derived homologue. Eur. J. Cancer 1994; 30A: 84 – 88
50. Hu L.F., Chen F., Zheng X., Ernberg I., Cao S.L., Christensson B., Klein G., Winberg G. Clonability and tumorigenicity of human epithelial cells expressing the EBV encoded membrane protein LMP1. Oncogene 1993; 8: 1575 – 1583
51. Pallesen G., Hamilton-Dutoit S.J., Rowe M., Young L.S. Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet 1991; i: 320 – 322
52. Herbst H., Dallenhach F., Hummel M., Niedobitek G., Pileri S., Muller-Lantzsch N., Stein H. Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells. Proc. Natl. Acad Sci. USA 1991; 88: 4766 – 4770
53. Hammarskjold M.L., Simurada M.C. Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-kB activity. J. Virol. 1992; 66: 6496 – 6501
54. Laherty C.D., Hu H.M., Opipari A.W., Wang F., Dixit V.M. The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor kB. J. Biol. Chem. 1992; 267: 24157 – 24160
55. Rothenberger S., Bachmann E., Knecht H. Natural 30 bp and 69 bp deletion variants of the LMP1 oncogene do stimulate NK-kB-mediated transcription. Oncogene 1996, (manuscript in revision)
56. Van de Stolpe A., Caldenhoven E., Stade B.G., Koenderman L., Raaijmakers J. A. M., Johnson R.P., van der Saag P.T. 12-O-tetradecanoylphorbol-13-acetate-and tumor necrosis factor α-mediated induction of intercellular adhesion molecule-1 is inhibited by dexamethasone. J. Biol. Chem. 1994; 269: 6185 – 6192
57. Martin J., Sugden B. Transformation by the oncogenic latent membrane protein correlates with its rapid turnover, membrane localization, and cytoskeletal association. J. Virol. 1991; 65: 3246 – 3258
58. Liu Y.-J., Joshua D.E., Williams G.T., Smith C.A., Gordon J., MacLennan I. C. M. Mechanism of antigen-driven selection in germinal centres. Nature 1989; 342: 929 – 931
59. Liu Y.J., Malisan F., de Bouteiller O., Guret C., Lebecque S., Banchereau J., Mills F.C., Max E.E., Martinez-Valdez H. Within germinal centers, isotype switching of immunoglobulin genes occurs after the onset of somatic mutation. Immunity 1996; 4: 241 – 250
60. Carbone A., Tirelli U., Gloghini A., Volpe R., Boiocchi M. Human immunodeficiency virus-associated systemic lymphomas may he subdivided into two main groups according to Epstein-Barr viral latent gene expression. J. Clin. Oncol. 1993; 11: 1674 – 1681
61. Hamilton-Dutoit S.J., Raphael M., Audouin J., Diebold J., Lisse I., Pedersen C., Oksenhendler E., Marelle L., Pallesen G. In situ demonstration of Epstein-Barr virus small RNAs (EBER 1) in acquired immunodeficiency syndrome-related lymphomas: correlation with tumor morphology and primary site. Blood 1993; 82: 69 – 624
62. Moorthy R.K., Thorley-Lawson D.A. All three domains of the Epstein-Barr virus-encoded latent membrane protein LMP-1 are required for transformation of Rat-1 fibroblasts. J. Virol. 1993; 67: 1638 – 1646
63. Seto E., Benedict Yen T.S., Matija Peterlin B., Ou J.-H. Trans-activation of the human immunodeficiency virus long terminal repeat by the hepatitis B virus X protein. Proc. Natl. Acad. Sci. USA 1988; 85: 8286 – 8290
64. Sun S.-C., Elwood J., Beraud C., Greene W.C. Human T-cell leukemia virus type 1 tax activation of NF-kB/Rel involves phosphorylation and degradation of IkBα and RelA (p65)-mediated induction of the c-rel gene. Mol. & Cell. Biol. 1994; 14: 7377 – 7384
65. Kanno T., Franzoso G., Siebenlist U. Human T-cell leukemia virus type 1 Tax-protein-mediated activation of NF-kB from p100 (NF-kB2)-inhibited cytoplasmic reservoirs. Proc. Natl. Acad. Sci USA 1994; 91: 12634 – 12638
66. Gruss H.-J., Brach M.A., Drexler H.G., Bonifer R., Mertelsmann R.H. Expression of cytokine genes, cytokine receptor genes, and transcription factors in cultured Hodgkin and Reed-Sternberg cells. Cancer Res. 1992; 52: 3353 – 3360
67. Bargou R.C., Leng C., Krappmann D., Emmerich F., Mapara M.K., Bommert K., Royer H.D., Scheidereit C., Doerken B. High-level nuclear NF-kB and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood 1996; 87: 4340 – 4347
68. Gruss H.J., Ulrich D., Dower S.K., Herrtmann F., Brach M.A. Activation of Hodgkin cells via the CD30 receptor induces autocrine secretion of interleukin-6 engaging the NF-kB transcription factor. Blood 1996; 87: 2443 – 2449
69. Baker S.J., Reddy E.P. Transducers of life nnd death: TNF receptor superfamily and associated proteins. Oncogene. 1996; 12: 1 – 9